Drug intelligence / Profile preview

ABI-7423

Development stage: Preclinical
Lead developer: Assembly Biosciences
Modality: Small Molecules
Administration: Oral

Overview

ABI-7423 is an investigational, oral, broad-spectrum non-nucleoside polymerase inhibitor being developed for the treatment of transplant-associated herpesviruses. It is designed to inhibit viral DNA polymerase activity, thereby blocking replication of a range of herpesviruses that can cause significant morbidity in immunocompromised patients, such as those undergoing organ transplantation. The drug is currently in IND/CTA-enabling studies and has not yet entered clinical trials. Assembly Biosciences is advancing this candidate as part of its antiviral pipeline targeting serious viral diseases[1][6][8].

Other names: broad-spectrum non-nucleoside polymerase inhibitorunnamed broad-spectrum polymerase inhibitor

Targets

DNA polymerase family

Beyond the preview

Go deeper on ABI-7423.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABI-7423.

Explore the full profile